332.97
+19.94%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Praxis Precision Medicines
From its filings with the US Securities and Exchange Commission
Praxis Precision Medicines is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PRAX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $303.3m. At that date it held total assets of $937.9m and shareholders' equity of $878.1m.
Our platforms utilize a deliberate, pragmatic and patient-guided approach, leveraging a suite of translational tools, including novel transgenic and predictive translational animal models and electrophysiology markers, to enable an efficient path to proof-of-concept in patients. Through this approach, we have established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy.
We have built Cerebrum™, enabled by innovative computational and experimental tools, to discover and develop first- and best-in-class CNS small molecule therapies. Our world-class ion channel discovery science team, along with external collaborators, accelerate our ability to create and execute novel screening cascades for our selected genetic targets. Fundamental to advancement of candidates are our multiscale disease models that link genetic cause to network function to elucidate novel drivers of disease phenotype. We employ translational biomarkers such as quantitative electroencephalography, or qEEG, to guide dose selection, with the goal of improving probability of success in the clinic. The precision application of our candidates is guided by genomics and informatics to identify, stratify and activate patients for trial recruitment and execution. To date, Cerebrum™ has generated three clinical stage product candidates, ulixacaltamide, vormatrigine and relutrigine, as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Quoted from its 10-K, filed 19 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Oct 2020
- Employees
- 168
- Website
- praxismedicines.com ↗
- Head office
- 99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Dean MitchellIndependent Chairman of the Board$388,977
- Mr. Marcio SouzaPresident, Chief Executive Officer, Director, since 2020$13.4m
- Mr. Timothy KellyChief Financial Officer$4.0m
- Ms. Megan SniecinskiChief Operating Officer
- Mr. Alex NemiroffGeneral Counsel, Corporate Secretary$3.9m
- Mr. Stuart ArbuckleIndependent Director
- Dr. Jeffrey ChodakewitzIndependent Director$356,269
- Dr. Merit CudkowiczIndependent Director$360,269
- Ms. Jill DesimoneIndependent Director$363,732
- Mr. Jeffrey KindlerIndependent Director
- Mr. Gregory NordenIndependent Director$368,317
- Mr. William YoungIndependent Director$361,440
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 36
- Environment
- 38
- Social
- 43
- Governance
- 27
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Praxis Precision Medicines Inc focuses on genetic epilepsies for CNS disorder therapies.
- Cerebrum platform develops orally precise therapies for neuronal imbalances.
- Solidus platform targets ASO therapies using computational methods.
Weaknesses
- The company employs 109 full-time employees as of 2020.
- Praxis Precision Medicines went public on October 16, 2020.
- The company has only two product candidates PRAX-944 and others.
Opportunities
- The Biotechnology sector in the US offers growth potential for CNS therapies.
- Boston, Massachusetts provides a strong biotech ecosystem for innovation.
- The focus on genetic insights can lead to new neurological disorder treatments.
Threats
- The Biotechnology industry faces high R&D costs and regulatory challenges.
- CNS disorder therapies require extensive clinical trials and approvals.
- Competition in the US biotech market is intense for neurological treatments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.